EPI (HOLDINGS) has granted a loan limit of 1.65 million New Zealand dollars.
Cheung Ying Group (Holdings) (00689) announced that on December 19, 2025, the lender EPI ESG Investment (New Zealand) Limited (an indirect wholly-owned subsidiary of the company in New Zealand) entered into a loan agreement with the borrower and mortgagor (Mr. Lion Yang), whereby the lender agreed to provide the borrower with a principal amount of NZ$1.65 million (approximately HK$7.425 million) with a repayment period of six months.
EPI (HOLDINGS)(00689) announcement that on December 19, 2025, the lender EPI ESG Investment (New Zealand) Limited (an indirect wholly-owned subsidiary of the company in New Zealand) entered into a loan agreement with the borrower and mortgagor (Mr. Lion Yang). According to this, the lender agreed to provide a loan amount of NZ $1.65 million (approximately HK $7.425 million) to the borrower, with a repayment period of six months.
The directors believe that the loan amount provided by the lender is in line with the company's plan to generate stable income, and is part of the group's everyday lending operations and general business operations. The terms of the loan agreement were reached after fair negotiation by all parties with reference to current commercial practices.
Related Articles
Shanghai Kinlita Chemical (300225.SZ) is planning to sell 34% equity stake in its affiliated company, Yitaiji Technology, to optimize asset allocation.
Yifang Biotechnology (688382.SH) intends to launch a restricted stock incentive plan for 2025.
Jiangsu Hengrui Pharmaceuticals (01276): HRS-6208 capsules, HRS-6209 capsules, HRS-8080 tablets, HRS-1358 tablets, and HRS-5041 tablets have been approved to conduct clinical trials.
Shanghai Kinlita Chemical (300225.SZ) is planning to sell 34% equity stake in its affiliated company, Yitaiji Technology, to optimize asset allocation.
Yifang Biotechnology (688382.SH) intends to launch a restricted stock incentive plan for 2025.
Jiangsu Hengrui Pharmaceuticals (01276): HRS-6208 capsules, HRS-6209 capsules, HRS-8080 tablets, HRS-1358 tablets, and HRS-5041 tablets have been approved to conduct clinical trials.
